Saturday 17 October 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.83
0.79
−3.83%
Follow NAMS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 8.09 | — | — | — | — | — |
Altman Z-Score |
27.63 | 13.11 | 7.43 | 3.45 | 10.24 | — | — | — | — | — |
P/S ratio |
184.61 | 53.22 | 43.24 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
8.19 | 9.69 | 4.25 | 14.38 | 15.05 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 19.92 | 0.00 | — | — | — | — | — |
P/Operating CF |
(101.63) | (64.70) | (29.69) | 18.52 | 57.20 | — | — | — | — | — |
P/B ratio |
6.08 | 3.20 | 3.40 | 0.49 | 0.00 | — | — | — | — | — |
Price to Tangible BV |
6.08 | 3.20 | 3.41 | 0.49 | 0.00 | — | — | — | — | — |
EV/Sales |
156.28 | 34.91 | 28.25 | 0.00 | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 2.40 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(23.80) | (10.03) | (4.54) | (23.94) | (235.43) | — | — | — | — | — |
EV/FCF |
(23.76) | (9.99) | (4.54) | (23.94) | (235.43) | — | — | — | — | — |
Quick Ratio |
7.43 | 7.85 | 6.82 | 12.97 | 0.00 | 5.52 | 0.00 | 5.77 | 5.77 | — |
Current Ratio |
7.88 | 8.08 | 6.95 | 13.26 | 12.64 | 6.70 | 5.96 | 7.90 | 7.90 | — |
Net Debt/EBITDA |
2.83 | 4.74 | 1.86 | 131.83 | 94.51 | 0.90 | 1.76 | 10.69 | 10.69 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.03 | 0.08 | 0.03 | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.73 | 0.66 | 0.80 | (0.47) | (0.10) | (0.03) | 0.88 | (12.05) | (12.05) | — |
Capex/Depreciation |
(1.12) | (5.95) | (0.49) | (24.56) | 0.00 | (1.43) | 0.00 | (13.00) | — | — |
Interest Coverage |
— | — | — | (12.39) | (866.88) | (6.33) | 0.00 | (0.37) | (283.78) | — |
| (28.29%) | (46.20%) | (49.25%) | (10.68%) | 0.00% | (49.46%) | 0.00% | 0.07% | 0.07% | — | |
| (24.95%) | (39.88%) | (42.86%) | (7.32%) | 0.00% | 2.99% | 0.00% | 0.03% | 0.06% | — | |
ROIC |
(307.51%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(34.53%) | (31.93%) | (59.59%) | (5.12%) | (18.62%) | 287.00% | 0.00% | 2.54% | 2.54% | — |
Average Days of Receivables |
0.00 | 39.66 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
630.28% | 332.30% | 1,131.47% | 84.47% | 84.34% | 0.00% | 0.00% | 0.00% | — | — |
Selling, General and Administrative Expense of Revenue |
472.62% | 154.61% | 267.09% | 19.00% | 20.49% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
264.08% | 73.79% | 174.39% | 4.01% | 0.00% | 0.00% | — | — | — | — |
Graham Net Nets |
0.14 | 0.31 | 0.29 | 2.02 | (4.27) | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(4.93%) | (10.12%) | (22.40%) | (10.66%) | 12.36% | — | — | — | — | — |
Free Cash Flow Yield |
(3.56%) | (6.57%) | (14.39%) | 5.02% | (0.41%) | — | — | — | — | — |
Revenue per Share |
0.19 | 0.48 | 0.17 | 5.41 | 1.26 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.25) | (1.68) | (1.72) | 0.56 | 0.10 | (0.04) | (1.23) | (0.16) | (0.03) | — |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(1.25) | (1.69) | (1.72) | 0.55 | 0.10 | (0.05) | (1.23) | (0.16) | (0.03) | — |
Cash per Share |
5.38 | 8.84 | 4.14 | 24.66 | 5.74 | 0.36 | 2.50 | 0.44 | 0.08 | — |
Shareholders Equity per Share |
5.77 | 8.03 | 3.51 | 22.68 | 6.34 | (1.84) | 2.35 | (3.39) | 7.18 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
5.77 | 8.03 | 3.51 | 22.68 | 6.34 | (1.84) | 2.35 | (3.39) | 7.18 | — |
Free Cash Flow |
(148.03) | (159.24) | (141.24) | 10.44 | 8.38 | (0.16) | (29.74) | (0.51) | (0.50) | — |
Working Capital |
589.91 | 756.50 | 296.89 | 441.92 | 440.42 | 1.27 | 55.72 | 1.63 | 1.63 | — |
Capital Expenditures |
(0.25) | (0.67) | (0.02) | (0.22) | (0.01) | (0.02) | (0.02) | (0.01) | — | — |
Net Current Asset Value |
589.85 | 756.29 | 288.09 | 429.55 | 428.04 | (144.38) | 55.59 | (148.54) | (10.54) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 71.78 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.57 | 0.47 | 1.07 | 0.26 | 0.49 | 0.07 | 0.08 | 0.00 | — | — |
Cash ROIC |
(11.21%) | (10.00%) | (22.46%) | 1.16% | 0.85% | 3.09% | (25.42%) | 5.59% | (0.39%) | — |
Accounts Receivable Turnover |
0.00 | 12.98 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | — | 0.00 | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | 0.00 | — | — | — |
Average Receivables |
— | 3.51 | — | — | 3.48 | — | — | — | — | — |
Average Payables |
6.86 | 10.83 | 14.39 | 6.01 | 6.01 | 0.16 | 3.62 | 0.16 | 0.16 | — |
Average Assets |
816.95 | 605.86 | 412.80 | 309.00 | 353.42 | 139.69 | 103.93 | 139.87 | 69.93 | — |
Average Common Equity |
720.47 | 522.95 | 359.23 | 211.85 | 255.37 | (8.45) | 23.04 | 58.46 | 58.46 | — |
Columns are period end dates